



www.centerforamericanprinciples.org

Center for American Principles Condemns New Medicare Pricing Rule

WASHINGTON September 30, 2026- the Centers for Medicare & Medicaid Services (CMS) issued the final rule for its proposed "Global Benchmark for Efficient Drug Pricing" (GLOBE) payment model, which would impose rebates on certain Medicare Part B medicines when U.S. prices exceed benchmarks derived from prices paid in foreign countries.

Anthony Zagotta, President of the Center for American Principles, issued the following statement in response:

"GLOBE purports to make medicines more [affordable](#) for patients. In reality, it represents a serious government overreach. Congress created the Center for Medicare and Medicaid Innovation to test limited and voluntary payment reforms, yet this so-called test program would impose sweeping drug price controls on a [quarter](#) of the Medicare market, threatening the private sector competition that underpins U.S. biomedical innovation.

"GLOBE would import foreign governments' price controls into the United States by tying what Medicare pays for certain Part B drugs to prices abroad. In other countries, artificial price restrictions consistently limit access to new medicines and reduce research investment. GLOBE risks bringing those access barriers here and undermining the development of future lifesaving treatments.

"There is also little evidence that this payment model would deliver the patient benefits it promises. In fact, studies indicate that GLOBE would provide [minimal out-of-pocket savings](#).

"American patients are depending on our nation's free market innovation model to deliver the new treatments they need. That system is also essential to maintaining America's biomedical leadership at a time when China is aggressively competing to overtake us. GLOBE would move the United States in exactly the wrong direction. We condemn this unlawful scheme in the strongest terms."

####